RESUMO
AIM: Vinpocetine (Vin) has long been used as a medicine to treat cerebrovascular disorders and as a dietary supplement to improve cognitive functions. Previous studies have revealed that the transcription factor nuclear factor kappa B (NF-κB) activity plays an important role in osteogenic differentiation of mesenchymal stem cells (MSC). Vin inhibits NF-κB-dependent inflammatory responses; however, the effect of Vin on the osteogenic differentiation of MSCs has not been reported. In this study, we aimed to the investigate effect of Vin on the osteogenic differentiation of rat bone marrow-derived MSCs (BMSCs). METHODS: We treated BMSCs with clinical plasma (0.17 µM) or higher concentrations (5 and 20 µM) of Vin with no significant effect on the cell viability. Alizarin Red S and alkaline phosphatase (ALP) stainings were used to evaluate mineralizations on days 14 and 21. Moreover, expressions of target genes were detected using qRT-PCR analysis. RESULTS: Osteogenic differentiation of BMSCs did not significantly change with Vin's clinical plasma concentration, but significantly decreased with higher concentrations. Calcium mineralization, ALP staining and mRNA gene expressions of Runx2 and ALP were decreased significantly with high concentrations of Vin, paticularly on day 21. CONCLUSION: Our in vitro findings suggest that clinically relevant concentration of Vin seems safe to use in elderly patients with respect to osteoporosis. On the other hand, Vin at high concentrations appears to be harmful to bone homeostasis.
Assuntos
Diferenciação Celular/efeitos dos fármacos , Células-Tronco Mesenquimais/efeitos dos fármacos , Osteogênese/efeitos dos fármacos , Alcaloides de Vinca/sangue , Alcaloides de Vinca/farmacologia , Fosfatase Alcalina/metabolismo , Animais , Células da Medula Óssea/efeitos dos fármacos , Calcificação Fisiológica/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Células Cultivadas , Subunidade alfa 1 de Fator de Ligação ao Core/biossíntese , Subunidade alfa 1 de Fator de Ligação ao Core/genética , Regulação da Expressão Gênica/efeitos dos fármacos , NF-kappa B/efeitos dos fármacos , RatosRESUMO
Ali Münsi (Bursa ? - Istanbul 1733), mostly known as Bursali Ali Münsi, is one of the most eminent physicians in the 18th century. He started education at a Bursa madrasa and attended courses given by many famous Ottoman physicians and scholars in various madrassas in Bursa. After completing his education in madrassa he was employed as a mudarris in Bursa and Istanbul madrassas. He was appointed to the Ottoman Palace and became a member of the royal physicians (etibba-yi hassa), because of his proficiency. Then, he was promoted and was officed as the head physician of the Galatasaray Enderun School. Ali Münsi has many works on medical practice, such as, Bida'at al-mübtedi, Cerrahnâme, Tuhfe-i aliyye and Altznotu Risalesi. Tuhfe-i Aliyye is known as the Kinakina Risalesi (chinchona), that is about how to treat a patient infected with malaria, by administering a drug named chinchona. Besides, it deals with the story of introducing chinchona to the Ottoman world from Europe. It was the first monography written on kinakina. There are several manuscripts of this text; for example, one is in the Bayezid Library, the other is in the Cerrahpasa Medical School Medical History Department. This article is a Turkish transliteration of the Süleymaniye manuscript.